NovoCure Ltd. ( (NVCR) ) has released its Q2 earnings. Here is a breakdown of the information NovoCure Ltd. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Novocure Ltd. is a global oncology company focused on extending survival in aggressive cancer forms through its innovative Tumor Treating Fields (TTFields) therapy.
In its second quarter of 2025, Novocure reported a 6% year-over-year increase in net revenues, reaching $159 million, driven by active patient growth in major markets. The company also highlighted significant clinical achievements, including the presentation of successful Phase 3 PANOVA-3 trial results at major oncology conferences.
Key financial metrics for the quarter include a gross margin of 74%, a net loss of $40.1 million, and an adjusted EBITDA of negative $9.9 million. The company experienced increased expenses in research, development, and marketing, reflecting its ongoing expansion efforts, particularly in the non-small cell lung cancer (NSCLC) market. Novocure’s cash and short-term investments stood at $911.5 million by the end of the quarter.
Operationally, Novocure reported 4,331 active patients on TTFields therapy globally, with a notable increase in Optune Gio active patients. The company is preparing for upcoming regulatory submissions for its TTFields therapy in pancreatic cancer and brain metastases from NSCLC, based on promising clinical trial results.
Looking ahead, Novocure remains focused on achieving its clinical and regulatory milestones, with plans to submit applications to the FDA for new indications and to continue expanding its market presence in the oncology sector.